Clinical Research Directory
Browse clinical research sites, groups, and studies.
Women at Risk of Breast Cancer and OLFM4
Sponsor: Institut Cancerologie de l'Ouest
Summary
Does the olfactomédine provide an help to limit the number of false positives in the overall imaging balance and limit the number of unnecessary biopsies?
Official title: Evaluation of the Circulating Concentration of Olfactomédine 4 (OLFM4) in Women With a BRCA1 or 2 Gene Mutation or at High Risk of Developing Breast Cancer, According to the Imaging
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2016-03-08
Completion Date
2026-03
Last Updated
2025-08-15
Healthy Volunteers
No
Interventions
OLFM4
patient have an additional blood test every 6 months for dosing OLFM4
Locations (4)
Institut de Cancerologie de l'Ouest
Angers, France
CHU Morvan
Brest, France
Instit de Cancérologie de l'Ouest
Nantes, France
CHBA Hopital Chubert
Vannes, France